SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
-------------------------------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): January 24, 2003
----------------
CYTOGEN CORPORATION
(Exact Name of Registrant as Specified in Charter)
Delaware 000-14879 222322400
--------------------------------------------------------------------------------
(State or Other Jurisdiction (Commission File Number) (IRS Employer
of Incorporation) Identification No.)
650 College Road East, 3rd Floor, Princeton, NJ 08540
--------------------------------------------------------------------------------
(Address of Principal Executive Offices) (Zip Code)
(609) 750-8200
------------------------------------------------
(Registrant's telephone number,
including area code)
-----------------------------------------------------------------
(Former Name or Former Address, if Changed Since Last Report)
Item 5. Other Events and Required FD Disclosure.
Product Update and Conference Call
On January 24, 2003, Cytogen Corporation (the "Company") issued a press
release announcing that it provided DRAXIMAGE Inc. ("DRAXIMAGE"), the
radiopharmaceutical subsidiary of DRAXIS Health Inc., with notice of termination
of each of its License and Distribution Agreement and Product Manufacturing and
Supply Agreement with respect to both of DRAXIS' BrachySeed(TM) I-125 and
BrachySeed(TM) PD-103 products. Cytogen provided such notice of termination upon
a determination that there is no reasonable expectation that DRAXIS can
consistently supply the BrachySeed products at quantities, activity levels, and
schedules amendable to commercial sale, which has negatively impacted Cytogen's
ability to market such products. Such press release is attached hereto as
Exhibit 99.1 and is incorporated herein by reference.
On January 27, 2003, the Company issued a press release announcing that it
will be hosting a conference call today, Monday, January 27, 2003, at 11:00 a.m.
Eastern Time regarding this matter. To participate in the call, dial
877-356-8058 or 706-643-7672. This call is also being webcast and can be
accessed through the Company's website at www.cytogen.com by selecting Investor
Relations. A replay of the conference call will be available on the website for
two weeks following the call and an audio replay will be available after the
conference call and lasting until midnight, February 25, 2003, by calling
800-642-1687 or 706-645-9291 and entering the conference ID number 7914576. Such
press release is attached hereto as Exhibit 99.2 and is incorporated herein by
reference.
A copy of the script with respect to the conference call is attached hereto
as Exhibit 99.3 and is incorporated herein by reference. The foregoing
descriptions of such press releases are qualified in their entirety by reference
to each such document.
Item 7. Financial Statements, Pro Forma Financial Information and
Exhibits.
(c) Exhibits.
Exhibit No. Description
----------- -----------
99.1 Press release of the Company dated January 24, 2003
99.2 Press release of the Company dated January 27, 2003
99.3 Script of conference call to be held on January 27,
2003
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Cytogen Corporation
By: /s/ Michael D. Becker
-------------------------------------
Michael D. Becker
President and Chief Executive Officer
Date: January 27, 2003